Abstract: A non-alcohol mouthwash composition without chemical antibacterial medicament is disclosed. The non-alcohol mouthwash composition includes from 0.03% to 1.5% of ?-polyglutamic acid (?-PGA) and from 0.5% to 4% of surfactant, all percentages based on the total weight of the mouthwash composition. The non-alcohol mouthwash composition preferably includes from 0.4% to 1.5% by weight, or more preferably from 0.8% to 1.3% by weight, of ?-PGA. Containing no chemical antibacterial medicament, the non-alcohol mouthwash composition can effectively inhibit bacterial growth in the oral cavity without irritating the oral mucosa.

Abstract: The present invention discloses a desensitizing toothpaste. Based on the total weight of the desensitizing toothpaste, the desensitizing toothpaste includes: from 5% to 40% by weight of DP-bioglass; from 1% to 5% by weight of thickening agents; from 25% to 35% by weight of humectant; and from 1% to 5% by weight of surfactant, wherein the DP-bioglass includes: 8.4% of Na2O, 40.6% of CaO, 39% of SiO2, and 12% of P2O5 based on the total weight of the DP-bioglass. With the implementation of the present invention, the indication of dentin hypersensitivity can be greatly relieved.

Abstract: A non-alcohol mouthwash composition without chemical antibacterial medicament is disclosed. The non-alcohol mouthwash composition includes from 0.03% to 1.5% of ?-polyglutamic acid (?-PGA) and from 0.5% to 4% of surfactant, all percentages based on the total weight of the mouthwash composition. The non-alcohol mouthwash composition preferably includes from 0.4% to 1.5% by weight, or more preferably from 0.8% to 1.3% by weight, of ?-PGA. Containing no chemical antibacterial medicament, the non-alcohol mouthwash composition can effectively inhibit bacterial growth in the oral cavity without irritating the oral mucosa.

Abstract: The invention provides a method for predicting the response of an EGFR-activating mutant subject suffering from a lung adenocarcinoma and receiving treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and a method for predicting prognosis in an EGFR-activating mutant subject suffering from a lung adenocarcinoma and receiving treatment with EGFR-TKI. In the methods of the invention, clustered genomic alterations in specific chromosomes (in particular chromosomes 5p, 7p, 8q or 14q) are determined as a tool for predicting the response or prognosis.

Abstract: Methods for determining a tumor in a human is disclosed. Also disclosed are methods for identifying adenocarcinoma, and methods for identifying squamous cell carcinoma in a human tumor sample. In addition, methods for predicting prognosis of metastasis and survival in a human having a tumor is disclosed.

Abstract: A cable clip has a body and a fastener. The body has two supporting arms and a connecting arm. Each supporting arm has two ends. The connecting arm is formed between corresponding ends of the supporting arms. The fastener is mounted pivotally on the connecting arm of the body and has a through hole and multiple side surfaces. Distances from the through hole to the side surfaces of the fastener are different. Then, rotating the fastener adjusts the side surfaces abutting a plug to different plugs in different sizes.

Abstract: A cable clip has a body and a fastener. The body has two supporting arms and a connecting arm. Each supporting arm has two ends. The connecting arm is formed between corresponding ends of the supporting arms. The fastener is mounted pivotally on the connecting arm of the body and has a through hole and multiple side surfaces. Distances from the through hole to the side surfaces of the fastener are different. Then, rotating the fastener adjusts the side surfaces abutting a plug to different plugs in different sizes.

Abstract: This invention provides a method for predicting the post-treatment survival prospect of a cancer patient based on the expression level(s) of microRNAs hsa-miR137, hsa-miR372, hsa-miR182*, hsa-miR221, and hsa-let-7a in that cancer patient.

Abstract: This invention provides a method for predicting the post-treatment survival prospect of a cancer patient based on the expression level(s) of microRNAs hsa-miR137, hsa-miR372, hsa-miR182*, hsa-miR221, and hsa-let-7a in that cancer patient.

Abstract: The present invention provides methods using a gene expression profiling analysis (1) to determine whether a human sample is a tumor using a gene set containing nucleic acid sequences of SEQ ID NOS: 1-7, 8-17 or 1-17; (2) to identify whether a tumor tissue is an adenocarcinoma (using a gene set containing nucleic acid sequences of SEQ ID NOS: 15, and 18-21) or a squamous cell carcinoma (using a gene set containing nucleic acid sequences of SEQ ID NOS: 22-27); and (3) to predict the prognosis of survival and metastasis in humans with tumor (using a gene set containing nucleic acid sequences of SEQ ID NOS:19, and 28-42 or SEQ ID NOS: 19, 29, 31, 40, and 42), particularly for those humans who are at the early stage of lung cancer. The gene expression profiling is preferably performed by cDNA microarray-based techniques and/or Real-Time Reverse Transcription-Polymerase Chain Reaction (Real-Time RT-PCR), and analyzed by statistical means.

Abstract: A cable clip has a body and a fastener. The body has two supporting arms and a connecting arm. Each supporting arm has two ends. The connecting arm is formed between corresponding ends of the supporting arms. The fastener is mounted pivotally on the connecting arm of the body and has a through hole and multiple side surfaces. Distances from the through hole to the side surfaces of the fastener are different. Then, rotating the fastener adjusts the side surfaces abutting a plug to different plugs in different sizes.